Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00110747 · ClinicalTrials.gov registry record · Phase 3
S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Non-Ablative Facial Laser Resurfacing in Adults
A Phase 3 study, sponsored by ZARS Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 54
- Enrollment target
NCT00110747 is a Phase 3 study that has completed, run by ZARS Pharma. The registered enrollment target is 54 participants.
The verdict
NCT00110747, a Phase 3 study, has completed, sponsored by ZARS Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 54 participants
- Enrollment target
Study Summary
Lasers are used for non-ablative resurfacing of facial rhytides, atrophic scars, and a variety of epidermal and dermal lesions. Pain associated with the non-ablative laser treatment has been described as moderate to severe. For this reason, local anesthesia is commonly used to eliminate or minimize the pain. S-Caine™ Peel (lidocaine 7% and tetracaine 7% cream) is a eutectic formulation of lidocaine and tetracaine. The purpose of this study is to evaluate if S-Caine Peel is effective in providing topical local dermal anesthesia for non-ablative facial laser resurfacing in adults.
Interventions
- DRUG Placebo Peel
- DRUG S-Caine™ Peel (lidocaine and tetracaine topical cream 7%/7%)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2005-06 |
| Est. Completion | 2005-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00110747
The ClinicalTrials.gov registry entry for NCT00110747 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ZARS Pharma, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Peel is the first listed.
NCT00110747 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00110747 about?
NCT00110747 is a clinical study titled "S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Non-Ablative Facial Laser Resurfacing in Adults". Lasers are used for non-ablative resurfacing of facial rhytides, atrophic scars, and a variety of epidermal and dermal lesions. Pain associated with the non-ablative laser treatment has been described as moderate to severe. For this reason, local anesthesia is commonly used to eliminate or minimize ...
What is the current status of trial NCT00110747?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 54 participants. The study started on 2005-06. Estimated completion is 2005-09.
What interventions are being tested in trial NCT00110747?
The interventions under investigation include: Placebo Peel (DRUG), S-Caine™ Peel (lidocaine and tetracaine topical cream 7%/7%) (DRUG).
Who is sponsoring clinical trial NCT00110747?
This trial is sponsored by ZARS Pharma, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.